Stryker Corporation

New York Stock Exchange
Back to all articles
Slightly Bearish -15

Atlas Wealth LLC Invests $12.08 Million in Stryker Corporation $SYK

📈 Atlas Wealth LLC purchased a new position of 36,760 shares valued at $12.08 million in Stryker during the first quarter.

📉 Czech National Bank increased its stake by 3.9% to own 90,755 shares worth $31.9 million in the fourth quarter.

🚀 Daymark Wealth Partners expanded its position by 436.0%, acquiring an additional 37,307 shares valued at $16.1 million.

📈 Varma Mutual Pension Insurance raised its stake by 10.5% to own 53,610 shares worth $18.8 million.

🚀 Wealthcare Advisory Partners grew its position by 265.2%, purchasing an additional 6,774 shares valued at $3.3 million.

📉 CIBC Bancorp USA acquired a new position in the third quarter worth $17.5 million.

🏦 Institutional investors collectively own 77.09% of Stryker Corporation's outstanding stock.

💸 Director Ronda E. Stryker sold 310,000 shares for $96.8 million on May 26th, reducing her stake by 13.87%.

💸 VP M Kathryn Fink sold 5,220 shares for $1.48 million on May 11th, decreasing her position by 28.44%.

📉 Insiders have sold a total of 323,264 shares valued at $100.7 million over the last three months.

📉 Stryker reported Q1 EPS of $2.60, missing the consensus estimate of $2.98 by $0.38.

💰 The company generated revenue of $6.02 billion, which was 2.6% higher than the prior year period.

📊 Stryker achieved a return on equity of 23.42% and a net margin of 13.20% for the quarter.

🎯 The firm set full-year 2026 guidance between $14.90 and $15.10 per share in earnings.

💵 Stryker announced a quarterly dividend of $0.88 per share to be paid on July 31st.

📈 The dividend represents an annualized yield of 1.1% with a payout ratio of 40.74%.

📉 Deutsche Bank set a price target of $315.00 in a research report issued on May 1st.

📉 Needham & Company lowered its price objective to $418.00 while maintaining a buy rating.

📉 Leerink Partners reduced its price target to $407.00 and set an outperform rating.

📈 BMO Capital Markets initiated coverage with an outperform rating and a $369.00 price target.

📉 Wells Fargo & Company reduced its target price to $418.00 with an overweight rating.

📊 MarketBeat reports an average analyst price target of $392.52 with a Moderate Buy consensus.

Bullish Signals
  • Atlas Wealth LLC initiated a new position in Stryker, purchasing shares valued at $12.08 million to make it its 19th largest holding.
  • Czech National Bank increased its stake by 3.9% during the fourth quarter, adding 3,366 shares to its portfolio.
  • Daymark Wealth Partners significantly expanded its position by 436.0%, acquiring an additional 37,307 shares in the fourth quarter.
  • Varma Mutual Pension Insurance raised its stake by 10.5% during the fourth quarter, purchasing an additional 5,100 shares.
  • Wealthcare Advisory Partners grew its position by 265.2%, acquiring an additional 6,774 shares in the fourth quarter.
  • CIBC Bancorp USA acquired a new position in Stryker during the third quarter worth $17.5 million.
  • Stryker achieved a return on equity of 23.42% and a net margin of 13.20% despite missing earnings estimates.
  • The company reported revenue growth of 2.6% year-over-year, reaching $6.02 billion for the quarter.
  • Stryker has set full-year 2026 guidance between $14.90 and $15.10 EPS, indicating management confidence in future performance.
  • The company announced a quarterly dividend of $0.88 per share with an annualized yield of 1.1%.
Risk Factors
  • Stryker reported earnings per share of $2.60, which missed the consensus estimate of $2.98 by $0.38.
  • The company's revenue of $6.02 billion fell short of analyst expectations of $6.34 billion for the quarter.
  • Director Ronda E. Stryker sold 310,000 shares worth $96.8 million, representing a 13.87% decrease in her personal stake.
  • Vice President M Kathryn Fink sold 5,220 shares worth $1.48 million, reducing her position by 28.44%.
  • Insiders have collectively sold 323,264 shares valued at $100.7 million over the last three months.
  • Deutsche Bank set a price target of $315.00, which is below the current market price implied by other targets.
  • Needham & Company decreased its price objective from $454.00 to $418.00 while maintaining a buy rating.
  • Leerink Partners lowered their price objective from $410.00 to $407.00 in a recent report.
  • Wells Fargo & Company reduced its target price on Stryker from $456.00 to $418.00.
  • The average analyst price target of $392.52 is lower than the previous high targets set by Needham and Wells Fargo.
Full Analysis
Atlas Wealth LLC established a new position in Stryker Corporation (NYSE:SYK) during the first quarter, purchasing 36,760 shares valued at approximately $12.08 million. This investment represents 1.5% of Atlas Wealth's portfolio and ranks as its 19th largest holding. Several other institutional investors also adjusted their stakes in the medical technology company during the fourth quarter, with Czech National Bank increasing its position by 3.9%, Daymark Wealth Partners growing theirs by 436.0%, Varma Mutual Pension Insurance raising its stake by 10.5%, and Wealthcare Advisory Partners expanding its holding by 265.2%. CIBC Bancorp USA also acquired a new position worth $17.5 million in the third quarter. Institutional ownership of Stryker stands at 77.09% as of the latest filings. However, insider selling activity has been notable recently. Director Ronda E. Stryker sold 310,000 shares on May 26th for a total value of $96.8 million, reducing her personal stake by 13.87%. Additionally, Vice President M Kathryn Fink sold 5,220 shares on May 11th for $1.48 million, decreasing her position by 28.44%. Over the last three months, insiders have collectively sold 323,264 shares valued at approximately $100.7 million, leaving 4.60% of the stock currently owned by insiders. Financially, Stryker reported quarterly earnings on April 30th that missed analyst expectations. The company posted earnings per share (EPS) of $2.60 against a consensus estimate of $2.98, and revenue reached $6.02 billion compared to the expected $6.34 billion. Despite the miss, the firm achieved a return on equity of 23.42% and a net margin of 13.20%, with revenue growing 2.6% year-over-year. The company has set full-year 2026 guidance between $14.90 and $15.10 per share, while analysts currently expect EPS of $14.99 for the current year. Stryker recently announced a quarterly dividend to be paid on July 31st to shareholders of record as of June 30th. The dividend amount is $0.88 per share, representing an annualized yield of 1.1% and a payout ratio of 40.74%. Analyst sentiment remains mixed with varying price targets; Deutsche Bank set a target of $315, Needham lowered its objective to $418 with a buy rating, Leerink Partners adjusted its target to $407, BMO Capital Markets initiated coverage with an outperform rating and $369 target, and Wells Fargo reduced its target to $418. The aggregate average price target from MarketBeat is $392.52 based on ratings ranging from Strong Buy to Hold.